SCHEMBL2572508

SCHEMBL2572508

CCOP(=O)(OCC)N(C)CC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MVD P53602 2/20 0.42
TSHR P16473 2/20 0.37
ACHE P22303 1/20 0.35
TDP1 Q9NUW8 2/20 0.34
TP53 P04637 1/20 0.34
PPARD Q03181 2/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
AOX1 Q06278 1/20 0.32
EYA2 O00167 1/20 0.31
APP P05067 1/20 0.31
ACE P12821 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
GAA P10253 1/20 0.31
FFAR3 O14843 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2565724 0.80 CA12 (0.47) TSHRACHETDP1PPARDCA12
SCHEMBL14740734 0.78 LPAR3 (0.50) TSHRTDP1PPARDMEN1KMT2A
SCHEMBL29597934 0.75 TSHR (0.46) TSHRACHETDP1TP53PPARD
SCHEMBL11762919 0.72 PPARD (0.45) TSHRACHETDP1TP53PPARD
SCHEMBL3097799 0.72 MVD (0.44) MVDTSHRACHETDP1TP53
SCHEMBL23457718 0.71 MVD (0.50) MVDTSHRACHETDP1TP53
SCHEMBL527443 0.70 MVD (0.40) MVDTSHRTDP1EYA2APP
SCHEMBL20356305 0.70 TSHR (0.40) TSHRACHETDP1TP53PPARD
SCHEMBL9791411 0.69 TSHR (0.50) TSHRACHETDP1TP53PPARD
Ammonia Solution, Strong SCHEMBL7761771 0.69 MVD (0.39) MVDTSHRTDP1EYA2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2384318-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS Ardelyx, Inc. (US) 2011-11-09 EP disclosed
WO-2010078449-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2010-07-08 WO disclosed